Avalyn Pharma Inc. 8-K

What Happened Avalyn Pharma Inc. announced on June 29, 2026 that it entered into a First Amendment to its Sublease with CRISPR Therapeutics, Inc., expanding its leased premises at 105 West First Street, Boston, MA. The space increases from approximately 8,774 rentable sq ft to approximately 13,708 rentable sq ft, and the parties agreed the Company’s future minimum lease payments will increase by about $924,000 over the remaining lease term. Except as modified by the amendment, the original Sublease (dated August 29, 2025) remains in effect.

Key Details

• Effective date of amendment: June 29, 2026.
• New premises size: ~13,708 rentable square feet (up from ~8,774).
• Increase in future minimum lease payments: approximately $924,000 over the remaining lease term.
• Sublandlord: CRISPR Therapeutics, Inc.; location: 105 West First Street, Boston, MA.

Why It Matters The amendment increases Avalyn’s occupied space and contractual lease obligations, raising future minimum lease payments by roughly $924,000. For investors, this means higher occupancy costs and potential increases to operating expenses and cash outflows over the remaining lease term. Other terms of the original sublease remain unchanged per the filing.